Railway Pension Investments Ltd lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 12.2% during the second quarter, HoldingsChannel reports. The fund owned 358,970 shares of the medical research company’s stock after selling 49,960 shares during the period. Thermo Fisher Scientific accounts for about 2.3% of Railway Pension Investments Ltd’s investment portfolio, making the stock its 16th biggest holding. Railway Pension Investments Ltd’s holdings in Thermo Fisher Scientific were worth $179,973,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the business. Elyxium Wealth LLC increased its stake in Thermo Fisher Scientific by 1.9% in the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after purchasing an additional 20 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. grew its position in shares of Thermo Fisher Scientific by 0.7% in the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after buying an additional 20 shares during the last quarter. Princeton Capital Management LLC raised its stake in Thermo Fisher Scientific by 2.4% during the 4th quarter. Princeton Capital Management LLC now owns 922 shares of the medical research company’s stock worth $534,000 after acquiring an additional 22 shares in the last quarter. Finally, TCI Wealth Advisors Inc. lifted its position in Thermo Fisher Scientific by 5.4% in the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock valued at $212,000 after acquiring an additional 22 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.
Thermo Fisher Scientific Price Performance
Shares of NYSE TMO opened at $618.83 on Tuesday. The company’s fifty day moving average is $561.73 and its two-hundred day moving average is $512.40. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a market capitalization of $228.81 billion, a P/E ratio of 33.29, a PEG ratio of 2.53 and a beta of 0.84. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $647.00.
Thermo Fisher Scientific Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.
Insider Activity
In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 in the last 90 days. Insiders own 0.33% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on TMO shares. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday. Piper Sandler increased their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Finally, Barclays lifted their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.
View Our Latest Stock Report on TMO
About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
